HEAD & NECK CANCERS

General Cancer

Results from a phase II trial demonstrated that cemiplimab, a PD-1 inhibitor, induced an overall response rate (ORR) of 47.5% in patients with metastatic cutaneous squamous cell carcinoma.

According to study results presented at the 2018 ASCO Annual Meeting, women with head and neck cancer (HNC) are less likely to recieve intensive chemotherapy and radiation when compared with their male counterparts.

In results of a large randomized trial of patients with head and neck cancer who had undergone radiation therapy, patients who used mobile and sensor technology to track their symptoms demonstrated reduced severity of their symptoms compared with patients who received standard care.